NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

COMparison Between All immunoTherapies for Multiple Sclerosis.

NCT03193866

CompletedN/A

Sponsor: Karolinska Institutet

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Rituximab

Countries: Sweden

The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based structured prospective follow-up cohort of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. The study will include both treatment naïve patients starting their first DMT and patients switching from a previous first line DMT (escalation/second-line).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

INCLUSION CRITERIA:

The study population consists of all patients with Clinically Isolated Syndrome (CIS) or RRMS who;

* Initiate a first MS DMT (treatment naïve), or Initiate a second ever DMT, of a different drug class than the first, regardless of time between drugs or reason for discontinuation("switchers") from 1st Jan 2011 to 30st June 2018, and
* Are followed at any of the University clinics of Sweden, and
* Consent to participation in COMBAT-MS core, and
* Are expected to be capable to follow study assessments.

EXCLUSION CRITERIA:

\- Patients with progressive forms of MS at start of therapy are not eligible

Locations (1)

Stockholm, Sweden